ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,297.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $57.19, for a total value of $14,297.50. Following the completion of the sale, the vice president now owns 56,488 shares of the company’s stock, valued at approximately $3,230,548.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, September 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.82, for a total transaction of $14,205.00.
• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.62, for a total transaction of $14,905.00.

ANI Pharmaceuticals Stock Up 0.8 %

Shares of ANI Pharmaceuticals stock opened at $60.12 on Friday. The firm’s 50 day moving average price is $59.37 and its 200-day moving average price is $62.46. The company has a market cap of $1.26 billion, a P/E ratio of 37.58 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals’s revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.06 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Truist Financial reiterated a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $77.00.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ANIP. Exchange Traded Concepts LLC lifted its holdings in shares of ANI Pharmaceuticals by 20.8% during the third quarter. Exchange Traded Concepts LLC now owns 12,056 shares of the specialty pharmaceutical company’s stock worth $719,000 after purchasing an additional 2,072 shares during the period. Kings Path Partners LLC raised its position in ANI Pharmaceuticals by 18.9% during the 3rd quarter. Kings Path Partners LLC now owns 19,418 shares of the specialty pharmaceutical company’s stock worth $1,158,000 after buying an additional 3,086 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $228,000. The Manufacturers Life Insurance Company boosted its holdings in shares of ANI Pharmaceuticals by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 1,211 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after acquiring an additional 209,272 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.